• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Advocacy
      • Fundamental Rights of People with ALS/MND and Caregivers
      • Advocacy Toolkit
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
      • Expanded Access
    • Care Services
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
    • Drugs in Clinical Trial
      • Amylyx – AMX0035
      • Biogen – Tofersen
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Orphazyme – Arimoclomol
      • T Regulatory Cell Therapies
    • Approved Drugs
      • Riluzole/Tiglutik
      • Radicava/Edaravone
      • Neudexta
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Webinars
    • Alliance Meeting
    • Allied Professionals Forum
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • International Symposium on ALS/MND
  • About
    • Who We Are
    • Board of Directors
    • Committees/Advisory Councils
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Governance Committee
      • Budget and Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
  • Members
    • Member Registration
    • Forgot Password

Associazione Italiana Sclerosi Laterale Amiotrofia

(AISLA)
Italy
Date founded: April 1983
Region covered:

Italy


Address:

Via G. B. Pergolesi
6
Milan
20124 Milano
Italy


Associazione Italiana Sclerosi Laterale Amiotrofia Activities

Office Hours: from Monday to Friday 09.00 to 17.00

  • Raise awareness of the disease
  • Inform and support patients and their families (bulletins, meetings)
  • Refer patients to centres and local support groups
  • Fund research
  • Promote contact and co-operation with sister organisations in other countries
  • Notiziario AISLA bulletin with four issues a year, meetings
  • Newsletter AISLA monthly
  • Specific ALS call center, managed by an expert team able to help in dealing with the disease’s problems.

Associazione Italiana Sclerosi Laterale Amiotrofia Branches/Chapters

58

Contacts

  • Dr. Massimo Mauro, President

Phone:

+39 02 66982114

Fax:

+39 02 67070197

Email:

segreteria@aisla.it

Website:

www.aisla.it

Facebook:

www.facebook.com/aisla

Twitter:

twitter.com/aislaonlus

Primary Sidebar

Back to all

Subscribe to our Bi-Monthly Newsletter

Fill out the form below to subscribe to the Alliance’s bi-monthly newsletter, packed with updates from members associations from around the world!

Footer

Keep in touch

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.

  • Email
  • Facebook
  • Instagram
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2022 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login